

Contact information

Professor Curzio Rüegg
Division of Experimental Oncology
155 Chemin des Boveresses
CH-1066 Epalinges
Switzerland
Tel: +41-21-692-5853
fax: +41-21-692-5872
curzio.ruegg@unil.ch
<http://www.unil.ch/deo>



Curzio Rüegg is director of the Division of Experimental Oncology at the Department of Oncology and associate Professor in the Faculty of Biology and Medicine at the University of Lausanne (UNIL),.

Education and training

1977 – 1985	School of Medicine, Basel, Switzerland
1986	Postgraduate course in experimental medicine and biology, University of Zurich, Switzerland
1986 – 1988	Postdoctoral Fellow, Department of Allergy and Inflammation, CIBA-GEIGY AG, Basel, Switzerland
1988 – 1989	Intern in Medicine, Department of Internal Medicine Ospedale San Giovanni, Bellinzona, Switzerland
1989 – 1993	Postdoctoral Fellow, Lung Biology Center, School of Medicine, University of California, San Francisco, USA

Professional appointments

1993 – 2005	Head of Research, CePO, Faculty of Biology and Medicine UNIL
2002 – 2006	Affiliate Member, Swiss Institute for Experimental Cancer Research (ISREC) Epalinges, Switzerland
2006 – present	Head, Division of Experimental Oncology, <i>Médecin Chef</i> , Centre Pluridisciplinaire d'Oncologie (CePO) – CHUV – UNIL

Academic appointments

1999 – 2003	Assistant Professor, UNIL
2003 – present	Associate Professor, UNIL

Other activities

Co-founder of Diagnoplex SA, a Health Science start-up company based in Epalinges, Switzerland, active in early detection and monitoring of cancer (www.diagnoplex.com)
Member of several scientific advisory boards or granting agencies, including INSERM, DGF, SENDO, INCA

Field of Interests

Endothelial cell adhesion and signalling
Vascular biology and tumor angiogenesis
Cancer invasion and metastasis

Selected publications

C. Rüegg, A. Yilmaz, G. Bieler, J. Bamat, P. Chaubert, and F. J. Lejeune (1998). Evidence for the involvement of endothelial cell integrin α V β 3 in the disruption of the tumor vasculature induced by TNF and IFN γ . *Nature Med.*, 4:408-414 (*with news and views article*)

O. Dormond, A. Foletti, C. Paroz, and C. Rüegg (2001). Nonsteroidal anti-inflammatory drugs inhibit α V β 3 integrin-mediated and Cdc42/Rac-dependent endothelial cell spreading, migration and angiogenesis. *Nature Med.*, 9:1041-1047

O. Dormond, M. Bezzi A. Mariotti and C. Rüegg (2002). Prostaglandin E₂ promotes integrin α V β 3-mediated endothelial cell adhesion, Rac activation, and spreading through a cAMP/PKA-dependent effect. *J. Biol. Chem.*, 277:45838-45846

G. Bieler, M. Hasimim, Y. Monnier, N. Imaizumi, M. Ameyar, J. Bamat, L. Ponsonnet, S. Chouaib, M. Grell, S. L. Goodman, F. Lejeune and C. Rüegg (2007). Distinctive role of integrin-mediated adhesion in TNF-induced PKB and NF- κ B activation and relevance to endothelial cell survival. *Oncogene*, 26:5722-32

Y. Monnier, P. Farmer, G. Bieler, N. Imaizumi, T. Sengstag, G.C. Alghisi, J.C. Stehle, L. Ciarloni, S. Andrejevic-Blant, R. Moeckli, R.O. Mirimanoff, S.L. Goodman, M. Delorenzi, C. Rüegg (2008). CYR61 and α V β 5 integrin cooperate to promote invasion and metastasis of tumors growing in pre-irradiated stroma. *Cancer Res*, 68:7323-7331

G-C. Alghisi, L. Ponsonnet, and C. Rüegg (2009). The integrin antagonist cilengitide activates α V β 3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. *PLoS ONE*, 4(2): e4449